AMSTERDAM, The Netherlands, Nov. 11, 2013 (GLOBE NEWSWIRE) -- uniQure B.V., a leader in human gene therapy, today announced that it has confidentially submitted a registration statement on Form F-1 to the U.S. Securities and Exchange Commission ("SEC") relating to a possible initial public offering of its ordinary shares. The number of ordinary shares to be offered and the price range for the offering have not yet been determined.
The initial public offering is expected to commence after the SEC completes the review process with respect to uniQure's registration statement, subject to market conditions and other considerations.
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. This press release is not intended to, and does not, constitute an offer of any securities for sale.
CONTACT: Gretchen Schweitzer +49 172 861 8540 Gschweitzer@macbiocom.comSource: uniQure